Inflammation in renal atherosclerotic disease

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 6, 2008, Pages 873-881

  Udani, Suneel M ^a   Dieter, Robert S ^b  

^a Jr Hospital of Cook County   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Chronic kidney disease; Nitric oxide; Renal atherosclerotic disease; Renal small vessel ischemia; Renin angiotensin aldosterone axis; Statin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; IRON CHELATING AGENT; MATRIX METALLOPROTEINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PIRFENIDONE; PLACEBO; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; ROSUVASTATIN; SIMVASTATIN; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA;

AGING; ATHEROSCLEROSIS; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; MITOCHONDRION; MUSCLE DISEASE; NEPHRITIS; NEPHROSCLEROSIS; NEPHROTOXICITY; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PATHOGENESIS; POPULATION RISK; PREVALENCE; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; TOBACCO DEPENDENCE; UPREGULATION; ANIMAL; ARTERIOSCLEROSIS; DISEASE COURSE; INFLAMMATION; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; PATHOPHYSIOLOGY;

ANIMALS; ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; KIDNEY DISEASES; RENAL ARTERY OBSTRUCTION;

EID: 48249099668     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.6.873     Document Type: Review

References (33)

1. Bloch M, Basile J. Clinical insights into the diagnosis and management of renovascular disease. Minerva Med. 95, 357-373 (2004).
2. Bloch M, Basile J. Clinical insights into the diagnosis and management of atherosclerotic renal disease. Curr. Atheroscler. Rep. 8, 412-420 (2006).
3. Dieter RS, Schmidt WS, Pacanowski JP, Jaff MR. Renovascular hypertension. Expert Rev. Cardiovasc. Ther. 3(3), 413-422 (2005).
4. Meier P, Rossert J, Plouin P, Bumier M. Atherosclerotic renovascular disease: beyond the renal artery stenosis. Nephrol. Dial. Transplant. 22, 1002-1006 (2007).
5. Vaziri N, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int. 56, 1492-1498 (1999),
6. Schnackenberg C. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 282, R335-R342 (2002).
7. Lai EY, Patzak A, Steege A et al. Contribution of adenosine receptors in the control of arteriolar tone and adenosine-Angiotensin II interaction. Kidney Int. 70, 690-698 (2006).
8. Eberhart W, Pfeilschifter J. Nitric oxide and vascular remodeling: spotlight on the kidney. Kidney Int. 72, S9-S16 (2007).
9. Binder CJ, Weiher H, Exner M, Kerjaschki D. Glomerular overproduction of oxygen radicals in mpv 17 gene-inactivated mice causes podocyte foot process flattening and proteinuria. Am. J. Pathol. 154, 1067-1075 (1999).
10. Greiber S, Müller B, Daemisch P, Pavenstädt H. Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage-colony-stimulating factor. J. Am. Soc. Nephrol. 13, 86-95 (2002).
11. Zoja C, Abbate M, Remuzzi G. Progression of chronic kidney disease: insights from animal models. Curr. Opin. Nephrol. Hypertens. 15, 250-257 (2006).
12. Olin J. Renal artery disease. Cardiol. Clin. 20, 547-562 (2002).
13. Camici M. Urinary detection of podocyte injury. Biomed. Pharmacother. 61, 245-249 (2007).
14. Pätäri A, Forsblom C, Havana M et al. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 52, 2969-2974 (2003).
15. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293, 1737-1745 (2005).
16. Chonchol M, Linas S. Diagnosis and management of ischemic nephropathy. Clin. J. Am. Soc. Nephrol. 1, 172-181 (2006).
17. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double blind, placebo-controlled study on the effect of the aldosterone receptor antagonist sprionolactone in patients who have persistent proteinuria and are on long-term Angiotensin-converting enzyme inhibitor therapy, with or without an Angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol. 1, 256-262 (2006).
18. Praga, M. Therapeutic measures in proteinuric nephropathy. Kidney Int. 68, S137-S141 (2005).
19. Chade A, Zhu X, Mushin O. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J. 20, 1706-1708 (2006).
20. Lecian D, Demova H, Lodererova A et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press. Res. 29, 135-143 (2006).
21. Sandbu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J. Am. Soc. Nephrol. 17, 2006-2016 (2006).
22. Douglas K, O'Malley P, Jackson J. Meta-analysis: the effect of statins on proteinuria. Ann. Intern. Med. 145, 117-124 (2006).
23. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr. Opin. Lipidol. 13, 637-644 (2002).
24. Waters DD. Safety of high-dose atorvastatin therapy. Am. J. Cardiol. 96, 69-75 (2005).
25. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr. Opin. Lipidol. 17, 626-630 (2006).
26. Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol. 94, 882-888 (2004).
27. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int. 68, 2131-2142 (2005).
28. Rajaram V and Joseph J. Role of adenosine antagonism in the cardio-renal syndrome. pathophysiology and therapeutic potential. Curr. Heart Fail. Rep. 153-157 (2007).
29. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC. The effects of kw-3902, an adenosine a1 receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol. 50, 1551-1560 (2007).
30. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2, 906-913 (2007).
31. Lin J, Lin-Tan D, Hsu K, Yu C. Environmental lead exposure and progression of chronic renal disease in patients without diabetes. New Engl. J. Med. 348, 277-286 (2003).
32. Swaminathan S, Shah SV. Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr. Opin. Nephrol. Hypetens. 17, 143-148 (2008).
33. Cheung C, Patel A, Shaheen N et al. The effect of statins on the progression of atherosclerotic renovascular disease. Nephron. Clin. Pract. 107, c35-c42 (2007).